Do you want to read an article? Please log in or register.
Renal Medullary Carcinoma: Establishing Standards in Practice
Genitourinary Cancer
Related content
Genitourinary Cancer
Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice
Urol Oncol.
Joseph RW, Chatta G, Vaishampayan U
doi: 10.1016/j.urolonc.2017.01.017.
Genitourinary Cancer
Microvascular and lymphovascular tumor invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: A validation study in clinical practice
BJU Int.
Bedke J, Heide J, Ribback S, Rausch S, de Martino M, Scharpf M, Haitel A, Zimmermann U, Pechoel M, Alkhayyat H, Shariat SF, Dombrowski F, Stenzl A, Burchardt M, Klatte T, Kroeger N
doi: 10.1111/bju.13984.
Endocrine and Neuroendocrine Tumors (NET)Head and Neck Cancer
International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma
J Clin Oncol
Xu B, Fuchs TL, Ahmadi S, Alghamdi M, Alzumaili B, Bani MA, Baudin E, Chou A, De Leo A, Fagin JA, Ganly I, Glover A, Hartl D, Kanaan C, Khneisser P, Najdawi F, Nigam A, Papachristos A, Repaci A, Spanheimer PM, Solaroli E, Untch BR, Barletta JA, Tallini G, Al Ghuzlan A, Gill AJ, Ghossein RA
doi: 10.1200/JCO.21.01329
RECOMMENDED
Genitourinary Cancer
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
No abstract available
Therapy management of metastatic prostate carcinoma in general practice
a ADT: Androgen-Deprivation Therapy
b MRI: Magnetic Resonance Imaging
c CYP17: 17α-hydroxylase/C17, 20-lyase or cytochrome-P450-17
ASCO® 2019
Genitourinary Cancer
Renal Cell Carcinoma
Rini et al. 2019. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. Oral presentation presented at: ASCO 2019 Congress; May 31–June 4; Chicago, IL, USA.
Genitourinary Cancer
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
Ann Oncol.
Choueiri TK, Motzer RJ, Rini BI, Haanen J, Campbell MT, Venugopal B, Kollmannsberger C, Gravis-Mescam G, Uemura M, Lee JL, Grimm MO, Gurney H, Schmidinger M, Larkin J, Atkins MB, Pal SK, Wang J, Mariani M, Krishnaswami S, Cislo P, Chudnovsky A, Fowst C, Huang B, di Pietro A, Albiges L
doi: 10.1016/j.annonc.2020.04.010.
Genitourinary Cancer
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
Lancet Oncol
Powles T, Plimack ER, Soulières D, Waddell T, Stus V, Gafanov R, Nosov D, Pouliot F, Melichar B, Vynnychenko I, Azevedo SJ, Borchiellini D, McDermott RS, Bedke J, Tamada S, Yin L, Chen M, Molife LR, Atkins MB, Rini BI
doi: 10.1016/S1470-2045(20)30436-8
Genitourinary Cancer
Biopsy Cell Cycle Proliferation Score Predicts Adverse Surgical Pathology in Localized Renal Cell Carcinoma
Eur Urol.
Tosoian JJ, Feldman AS, Abbott MR, Mehra R, Tiemeny P, Wolf JS Jr, Stone S, Wu S, Daignault-Newton S, Taylor JMG, Wu CL, Morgan TM
doi: 10.1016/j.eururo.2020.08.032.